Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A G Beck-Sickinger

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Molecular Pharmacology|October 1, 1992
Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacyM C Michel, W Gaida, A G Beck-Sickinger, et al.
British Journal of Pharmacology|February 5, 2016
Pancreatic polypeptide and its central Y4 receptors are essential for cued fear extinction and permanent suppression of fearD Verma, B Hörmer, K Bellmann-Sickert, et al.
Physical Chemistry Chemical Physics : PCCP|August 6, 2016
Peptides@mica: from affinity to adhesion mechanismA Gladytz, T John, T Gladytz, et al.
Molecular Pharmacology|August 1, 1996
Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptorM Sautel, K Rudolf, H Wittneben, et al.
British Journal of Pharmacology|August 23, 2016
High molecular weight PEGylation of human pancreatic polypeptide at position 22 improves stability and reduces food intake in miceV Thieme, N Jolly, A N Madsen, et al.
Diabetologia|April 6, 2011
Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effectsN Klöting, P Kovacs, M Kern, et al.
European Journal of Pharmacology|December 27, 1994
The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226K Rudolf, W Eberlein, W Engel, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|March 21, 2007
New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumorsE García Garayoa, C Schweinsberg, V Maes, et al.
FEBS Letters|September 30, 1996
Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y2 receptorB Rist, O Zerbe, N Ingenhoven, et al.
Journal of Cachexia, Sarcopenia and Muscle|June 1, 2026
Novel Long-Acting Ghrelin Analogue PEP-064 Restores Energy Balance in C26 and Lewis Lung Carcinoma-Induced cachexia in MiceJ E Hunt, C Lund, B Chen, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Molecular Pharmacology|October 1, 1992
Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacyM C Michel, W Gaida, A G Beck-Sickinger, et al.
British Journal of Pharmacology|February 5, 2016
Pancreatic polypeptide and its central Y4 receptors are essential for cued fear extinction and permanent suppression of fearD Verma, B Hörmer, K Bellmann-Sickert, et al.
Physical Chemistry Chemical Physics : PCCP|August 6, 2016
Peptides@mica: from affinity to adhesion mechanismA Gladytz, T John, T Gladytz, et al.
Molecular Pharmacology|August 1, 1996
Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptorM Sautel, K Rudolf, H Wittneben, et al.
British Journal of Pharmacology|August 23, 2016
High molecular weight PEGylation of human pancreatic polypeptide at position 22 improves stability and reduces food intake in miceV Thieme, N Jolly, A N Madsen, et al.
Diabetologia|April 6, 2011
Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effectsN Klöting, P Kovacs, M Kern, et al.
European Journal of Pharmacology|December 27, 1994
The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226K Rudolf, W Eberlein, W Engel, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|March 21, 2007
New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumorsE García Garayoa, C Schweinsberg, V Maes, et al.
FEBS Letters|September 30, 1996
Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y2 receptorB Rist, O Zerbe, N Ingenhoven, et al.
Journal of Cachexia, Sarcopenia and Muscle|June 1, 2026
Novel Long-Acting Ghrelin Analogue PEP-064 Restores Energy Balance in C26 and Lewis Lung Carcinoma-Induced cachexia in MiceJ E Hunt, C Lund, B Chen, et al.
Pageof 10